Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial
Commissariat à l'Énergie Atomique et aux Énergies Alternatives · Hotel Dieu Hospital · +60 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
107
total citations
- FWCI
- 43.34
- Percentile
- 100%
- References
- 31
Citations per year
Authors
50- PMPhilippe MoreauCorresponding
Commissariat à l'Énergie Atomique et aux Énergies Alternatives, Hotel Dieu Hospital, Centre Hospitalier Universitaire de Nantes, CEA Cadarache
- CHCyrille Hulin
Centre Hospitalier Universitaire de Bordeaux, Hôpital Cardiologique du Haut-Lévêque
- APAurore Perrot
Centre Hospitalier Universitaire de Toulouse, Institut universitaire du cancer de Toulouse Oncopole
- BABertrand Arnulf
Université Paris Cité, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Louis
- KBKarim Belhadj
Centre Hospitalier Universitaire Henri-Mondor
Topics & keywords
Topics
Keywords
- Daratumumab
- Medicine
- Bortezomib
- Multiple myeloma
- Thalidomide
- Internal medicine
- Oncology
- Regimen
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.